Exelixis, Inc. (EXEL): Revenue
$2.32B
Year ended 2026-01-02, Fiscal 2025
$2.44B
Trailing 12 months to 2026-07-03
+12.9%
3-year compound annual growth
+18.6%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-01-02, Fiscal 2025 | $2.32B | +7.0% | 2026-02-10, From 2025-01-04 |
| 2025-01-03, Fiscal 2024 | $2.17B | +18.5% | 2026-02-10, From 2023-12-30 |
| 2023-12-29 | $1.83B | +13.6% | 2026-02-10, From 2022-12-31 |
| 2022-12-30 | $1.61B | +12.3% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $1.43B | +45.3% | 2024-02-06, From 2021-01-02 |
| 2021-01-01, Fiscal 2020 | $987.54M | +2.0% | 2023-02-07, From 2020-01-04 |
| 2020-01-03, Fiscal 2019 | $967.77M | +13.3% | 2022-02-18, From 2018-12-29 |
| 2018-12-28 | $853.83M | +88.7% | 2021-02-11, From 2018-01-01 |
| 2017-12-29 | $452.48M | +136.3% | 2020-02-25, From 2016-12-31 |
| 2016-12-30 | $191.45M | +415.0% | 2019-02-22, From 2016-01-02 |
| 2016-01-01, Fiscal 2015 | $37.17M | +48.0% | 2018-02-26, From 2015-01-03 |
| 2014-12-31 | $25.11M | -19.9% | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | $31.34M | -34.0% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $47.45M | -83.6% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $289.64M | +56.5% | 2014-02-20, From 2011-01-01 |
| 2010-12-31 | $185.04M | +21.9% | 2013-02-21, From 2010-01-01 |
| 2009-12-31 | $151.76M | n/a | 2012-02-22, From 2009-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.32B | +7.0% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $2.09B | +5.7% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $1.94B | -39.9% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $2.86B | +21.4% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $1.40B | +37.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.22B | -0.4% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.12B | +64.7% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $874.84M | +94.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $738.26M | +16.4% |
Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗